Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Deucravacitinib（一种酪氨酸激酶 2 抑制剂）治疗系统性红斑狼疮：一项 II 期随机、双盲、安慰剂对照试验
期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.42391
Morand, Eric; Pike, Marilyn; Merrill, Joan T; van Vollenhoven, Ronald; Werth, Victoria P; Hobar, Coburn; Delev, Nikolay; Shah, Vaishali; Sharkey, Brian; Wegman, Thomas; Catlett, Ian; Banerjee, Subhashis; Singhal, Shalabh
